Journal ArticleDOI
Doxorubicin-Induced Cardiomyopathy
TLDR
The tumors most commonly responding to doxorubicin when it is given as a single agent or in combination with other antitumor agents include breast and esophageal carcinomas; osteosarcoma, Kaposi's sarcoma and soft-tissue sarcomas; and Hodgkin's and non-Hodgkin's lymphomas.Abstract:
Doxorubicin (Adriamycin) has been used in oncologic practice since the late 1960s. It held promise as a powerful drug in the fight against cancer. The tumors most commonly responding to doxorubicin when it is given as a single agent or in combination with other antitumor agents include breast and esophageal carcinomas; osteosarcoma, Kaposi's sarcoma, and soft-tissue sarcomas; and Hodgkin's and non-Hodgkin's lymphomas. Other cancers that are less responsive to doxorubicin but that are still treated with the drug because of its overall benefits include gastric, liver, bile-duct, pancreatic, and endometrial carcinomas. However, reports of fatal cardiotoxic effects of doxorubicin have . . .read more
Citations
More filters
Journal ArticleDOI
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
TL;DR: An overview of issues confirms that anthracyclines remain “evergreen” drugs with broad clinical indications but have still an improvable therapeutic index.
Journal ArticleDOI
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
Mary O'Brien,Nely Wigler,Moshe Inbar,R. Rosso,E. Grischke,Armando Santoro,Raphael Catane,D. G. Kieback,Piotr Tomczak,Stephen P. Ackland,F. Orlandi,L. Mellars,L. Alland,C. Tendler +13 more
TL;DR: In first-line therapy for MBC, PLD provides comparable efficacy to doxorubicin, with significantly reduced cardiotoxicity, myelosuppression, vomiting and alopecia.
Journal ArticleDOI
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Sui Zhang,Xiaobing Liu,Xiaobing Liu,Tasneem Bawa-Khalfe,Long Sheng Lu,Yi Lisa Lyu,Leroy-Fong Liu,Edward T.H. Yeh,Edward T.H. Yeh +8 more
TL;DR: Cardiomyocyte-specific deletion of Top2b (encoding topoisomerase-IIβ) protects cardiomyocytes from doxorubicin-induced DNA double-strand breaks and transcriptome changes that are responsible for defective mitochondrial biogenesis and ROS formation.
Journal ArticleDOI
Role of oxidative stress in cardiovascular diseases.
TL;DR: The existing evidence support the view that oxidative stress may play a crucial role in cardiac and vascular abnormalities in different types of cardiovascular diseases and that the antioxidant therapy may prove beneficial in combating these problems.
Journal ArticleDOI
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Andrew D. Seidman,Clifford A. Hudis,Mary Kathryn Pierri,Steven Shak,Virginia E. Paton,Mark Ashby,Maureen E. Murphy,Stanford J. Stewart,Deborah L. Keefe +8 more
TL;DR: Trastuzumab is associated with an increased risk of cardiac dysfunction, which is greatest in patients receiving concurrent anthracyclines, and in most patients with metastatic breast cancer, the risk of CD can be justified given the improvement in overall survival previously reported with trastuzUMab.
References
More filters
Journal ArticleDOI
Risk factors for doxorubicin-induced congestive heart failure.
TL;DR: There was a continuum of increasing risk as the cumulative amount of administered drug increased, and a weekly dose schedule of doxorubicin was associated with a significantly lower incidence of congestive heart failure than was the usually employed every 3-week schedule.
Journal ArticleDOI
A clinicopathologic analysis of adriamycin cardiotoxicity
TL;DR: It is suggested that the total dose of adriamycin should be limited to less than 550 mg/m2 to permit safer use of this efficacious cancer chemotherapeutic agent.
Journal ArticleDOI
Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
TL;DR: The 23% incidence of late cardiac abnormalities warrants continued evaluation of patients after anthracyclines to guide patient care and the design of future chemotherapeutic protocols.
Journal ArticleDOI
The anthracyclines: will we ever find a better doxorubicin?
TL;DR: Current studies are evaluating increased doses of epirubicin to improve anthracycline cytotoxicity, while limiting cardiotoxicity, but at present DOX still reigns in this drug class as the one having the most proven cancerocidal effect.
Journal ArticleDOI
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.
Sewa S. Legha,Robert S. Benjamin,Bruce Mackay,Michael S. Ewer,Sidney Wallace,Manuel Valdivieso,Shelley L. Rasmussen,George R. Blumenschein,Emil J. Freireich +8 more
TL;DR: Cutting peak plasma levels of doxorubicin by continuous infusion reduces cardiotoxicity, and thus lessen cardiac toxicity, in patients treated by standard intravenous injection.